Capricor Therapeutics 株価情報 (NASDAQ: CAPR)

最新ニュース Capricor Therapeutics (NASDAQ:CAPR) 株価情報

CAPRICOR THERAPEUTICS INC

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

<p><strong>Capricor Therapeutics </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) on Friday <a href="https://dmdwarrior.com/capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy/?_gl=1&#x2A;9g80lr&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA0NDUyNDkkbzQ1MiRnMSR0MTc1MDQ0NjQxOSRqMTUkbDAkaDExNjcwNDQzNDI.">released</a> four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company&#8217;s lead cell therapy candidate for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.</p>
<p>After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline.</p>
<p>Further, a subgroup analysis of patients with baseline Left Ventricular Ejection Fraction (LVEF) &gt;45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44115317/capricor-therapeutics-cell-therapy-goes-under-priority-fda-review-for-duchenne-associated-heart-condition" rel="noreferrer noopener">Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition</a></strong></p>
<p>Additionally, treatment continued to slow skeletal muscle disease progression, as measured by performance of the upper limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the <a href="https://www.benzinga.com/pressreleases/25/06/g46025161/capricor-therapeutics-announces-positive-4-year-data-from-hope-2-open-label-extension-study-of-der" target="_blank" rel="noreferrer noopener">first year (1.8 points)</a>.</p>
<p>Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study.</p>
<p>&#8220;These four-year data reinforce the strength and durability of Deramiocel&#8217;s clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,&#8221; said <strong>Linda Marbán</strong>, CEO of Capricor Therapeutics. &#8220;With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval.</p>
<p><strong>CAPR Price Action:</strong> CAPR stock is down 31.75% at $8.16&nbsp;at publication on Friday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Biotech

News

Health Care

Movers

Trading Ideas

General

CAPR

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

WIIM

Capricor Therapeutics shares are trading lower following a report suggesting the FDA's Center for Biiologics Evaluation and Research canceled an advisory committee meeting due to skepticism about the company's therapy.

<p><a href="https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/">https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/</a></p>


'Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official'- STAT News

Capricor Therapeutics Shares Resume Trade

Capricor Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 36.5%

<h3>Gainers</h3>
<ul>
<li><strong>Innovative Eyewear</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock rose 84.4% to $4.21 during Friday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li><strong>SS Innovations</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 43.27% to $6.99. The market value of their outstanding shares is at $944.7 million. </li>
<li><strong>Anbio Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares rose 41.89% to $16.4. The market value of their outstanding shares is at $507.3 million. </li>
<li><strong>Processa Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares increased by 32.68% to $0.32. The company's market cap stands at $2.8 million. </li>
<li><strong>Citius Oncology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 29.67% to $2.01. The market value of their outstanding shares is at $110.9 million. </li>
<li><strong>Quantum BioPharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares increased by 23.92% to $37.4. The market value of their outstanding shares is at $87.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>SeaStar Medical Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares fell 66.7% to $0.32 during Friday's regular session. The market value of their outstanding shares is at $10.3 million. </li>
<li><strong>Moleculin Biotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares declined by 48.89% to $0.3. The company's market cap stands at $8.2 million. </li>
<li><strong>Regencell Bioscience</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 43.12% to $36.03. The company's market cap stands at $824.3 million. </li>
<li><strong>Capricor Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 22.74% to $9.22. The company's market cap stands at $545.7 million. </li>
<li><strong>Aptevo Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 21.64% to $4.02. The company's market cap stands at $3.4 million. </li>
<li><strong>Galectin Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares fell 21.59% to $2.58. The market value of their outstanding shares is at $208.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


APVO

CTOR

GALT

LUCY

MBRX

NNNN

PCSA

QNTM

SSII

12 Health Care Stocks Moving In Friday's Intraday Session

Capricor Therapeutics Announces 4-Year Data From HOPE-2 Open-Label Extension Study Of Deramiocel In Duchenne Muscular Dystrophy; After Four Years Of Continuous Treatment, Deramiocel-Treated Patients Showed A Median Change Of -0.5 Points Compared To Baseline

<p>U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.</p>
<p>Shares of <strong>Smith &amp; Wesson Brands Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) fell sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46007280/smith-wesson-q4-earnings-revenue-eps-fall-short-of-estimates-as-demand-slips-headwinds-will-likely-persist">worse-than-expected fourth-quarter EPS and sales.</a></p>
<p>Smith &amp; Wesson Brands reported fourth-quarter revenue of $140.8 million, missing analyst estimates of $152.41 million, according to Benzinga Pro. The company reported adjusted earnings of 20 cents per share in the fourth quarter, missing estimates of 23 cents per share.</p>
<p>Smith &amp; Wesson Brands shares dipped 12.6% to $9.51 in the pre-market trading session.</p>
<p>Here are some other stocks moving lower in pre-market trading.</p>
<ul class="wp-block-list">
<li><strong>Regencell Bioscience Holdings Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li><strong>QuantaSing Group Ltd- ADR</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li><strong>Aptevo Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li><strong>Capricor Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li><strong>Mesoblast Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
<li><strong>Diginex Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) dropped 6.5% to $43.51 in pre-market trading.</li>
<li><strong>Himalaya Shipping Ltd</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NASDAQ">HSHP</a>) declined 6.3% to $6.22 in pre-market trading.</li>
<li><strong>AIRO Group Holdings, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) fell 5.3% to $24.88 in pre-market trading.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Pre-Market Outlook

Markets

AIRO

DGNX

HSHP

MESO

SWBI

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<p>Shares of <strong>Cheetah Mobile Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) rose sharply in pre-market trading following <a href="https://www.benzinga.com/quote/cmcm/earnings">first-quarter results</a>.</p>
<p>Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's quarterly sales rose to $35.69 million from $26.35 million in the year-ago period.</p>
<p>Cheetah Mobile shares surged 11.2% to $4.57 in the pre-market trading session.</p>
<p>Here are some other stocks moving in pre-market trading.</p>
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li><strong>Wheeler Real Estate Investment Trust, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) surged 129.6% to $7.85 in pre-market trading. On May 21, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split.</li>
<li><strong>Dragonfly Energy Holdings Corp</strong>.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares jumped 108% to $0.4534 in pre-market trading after gaining 6% on Wednesday.</li>
<li><strong>Baiya International Group Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) gained 36.2% to $1.13 in pre-market trading.</li>
<li><strong>Processa Pharmaceuticals, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) jumped 32.2% to $0.32 in pre-market trading. On Tuesday, Processa Pharmaceuticals announced the pricing of $7 million public offering.</li>
<li><strong>GMS Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) rose 21.2% to $98.22 in pre-market trading. GMS confirmed the receipt of $95.20 per share unsolicited buyout proposal from QXO.</li>
<li><strong>Beasley Broadcast Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) rose 19.5% to $5.57 in pre-market trading after gaining 5% on Wednesday.</li>
<li><strong>Arqit Quantum Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 15.2% to $43.74 in pre-market trading after surging over 22% on Wednesday.</li>
<li><strong>Oscar Health, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) fell 13.3% to $21.31 in pre-market trading after gaining more than 16% on Wednesday.</li>
<li><strong>GeoVax Labs, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) climbed 10.4% to $1.02 in pre-market trading. GeoVax Labs recently in a filing disclosed it will sell 6.15 million common units.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li><strong>Nature Wood Group Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares tumbled 52.8% to $2.66 in pre-market trading after surging over 142% on Wednesday.</li>
<li><strong>Regencell Bioscience Holdings Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li><strong>PTL Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) dipped 16.2% to $0.30 in pre-market trading after surging 84% on Wednesday.</li>
<li><strong>Cambium Networks Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) declined 12.9% to $0.36 in pre-market trading after gaining over 16% on Wednesday. Cambium Networks, last month, announced it received a Nasdaq noncompliance notice.</li>
<li><strong>Smith &amp; Wesson Brands Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) declined 12.6% to $9.51 in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.</li>
<li><strong>Cellectar Biosciences In</strong>c (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 12.4% to $0.32 in pre-market trading. Cellectar Biosciences announced a 1-for-30 reverse stock split, effective June 24.</li>
<li><strong>QuantaSing Group Ltd- ADR</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li><strong>Aptevo Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li><strong>Capricor Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li><strong>Mesoblast Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


ARQQ

BBGI

BIYA

CLRB

CMBM

CMCM

DFLI

GOVX

NWGL

OSCR

PTLE

WHLR

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

<p>Roth Capital  analyst Boobalan Pachaiyappan   reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $31 price target.</p>


Price Target

Reiteration

Analyst Ratings

Roth Capital Reiterates Buy on Capricor Therapeutics, Maintains $31 Price Target

Capricor Therapeutics Granted Orphan Drug Designation For Deramiocel In Becker Muscular Dystrophy

<p>High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CAPR often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $29,500, and 9 calls, totaling $529,340.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $30.0 for Capricor Therapeutics over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Capricor Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Capricor Therapeutics's significant trades, within a strike price range of $7.5 to $30.0, over the past month.</p>
<h3>Capricor Therapeutics Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750096862_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$6.8</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$17.50</td>
<td>$154.5K</td>
<td align="right">281</td>
<td align="right">376</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.9</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$17.50</td>
<td>$60.0K</td>
<td align="right">281</td>
<td align="right">700</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.6</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$17.50</td>
<td>$56.0K</td>
<td align="right">281</td>
<td align="right">576</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.6</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$17.50</td>
<td>$56.0K</td>
<td align="right">281</td>
<td align="right">476</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.8</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$17.50</td>
<td>$56.0K</td>
<td align="right">281</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Capricor Therapeutics</h3>
<p>Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.</p>
<h3>Current Position of Capricor Therapeutics</h3>
<ul>
<li>With a trading volume of 1,289,638, the price of CAPR is up by 0.25%, reaching $11.81.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 51 days from now.</li>
</ul>
<h3>What The Experts Say On Capricor Therapeutics</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $77.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $77. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capricor Therapeutics with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Decoding Capricor Therapeutics's Options Activity: What's the Big Picture?

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.</p>


HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

<ul>
<li><i>U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensure</i></li>
<li><i>Advisory Committee meeting scheduled for July 30, 2025</i></li>
<li><i>Mid-cycle meeting recently completed with no significant issues or major deficiencies; late-cycle meeting planned for mid-July</i></li>
<li><i>Biologics License Application remains under priority review with PDUFA target action date of August 31, 2025</i></li>
</ul>
<p>SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9kv0YQSsvuNkhlhL4hq0BxY-mvGVz9Hqr-UioWaWL91aJvQHfavtwdOgN938MQx15_os5XeeSiSDBe52Iv9PwCw1Pw5dq3kfF0YATlEUg6unYAy8ArcXFOhwRgGcbYlYDs0plIWbj5_Kbpq-BsuOQhhyTT2LU7rIrVKI56WRqM4-1iw3FLaoW8eqLvdaG60J8Zl5gypHM7hgTtLXp29xh3Wp4S8fa2EerJSmvC4B1eB9XLivr97R4GdOJigW77Sr5ITdkGxWzwgK-Be0Obo-F8Sv_pxcGYQXVgx1aJWdQzhCFDBfqNk5zeNXLblcdWDzQaHQfXqH1Z1eeLG8U6d6qPQiUSMD2V4KWqYa18ZDqvfcTl1OX4hVzwEZGXSxRvwpww8DTw7VscxDuU3AwEVpTHBrjxK72WvAzMEGWCNZ4bGODqq2VFqY5J-J_fbo9Y8_K6byyMM8wXgIREFw2oLWhH0k3iqeauT6vy_GExWCNcxkZwtQ8_aGsVqRJpvKsa1D">Capricor Therapeutics</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of the U.S. Food and Drug Administration's (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the Company's lead cell therapy candidate with a Biologics License Application (BLA) under FDA review for potential approval in the treatment of Duchenne Muscular Dystrophy (DMD). The inspection concluded with a Form 483 containing several observations. The Company has submitted its responses to the FDA, none of which required material changes to the cGMP process or facility. The observations were primarily related to routine quality systems and documentation practices. The Company is confident that the facility will meet the necessary requirements to support product licensure and, pending approval, commercial launch.</p>


FDA Completes Pre-License Inspection Of Capricor Therapeutics' San Diego Manufacturing Facility For Deramiocel; Company Expects Facility Will Meet All Requirements To Support Licensure

<p>Financial giants have made a conspicuous bullish move on Capricor Therapeutics. Our analysis of options history for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 54% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $68,170, and 9 were calls, valued at $673,600.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $20.0 for Capricor Therapeutics, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Capricor Therapeutics stands at 520.67, with a total volume reaching 4,570.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Capricor Therapeutics, situated within the strike price corridor from $5.0 to $20.0, throughout the last 30 days.</p>
<h3>Capricor Therapeutics Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749585738_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$9.7</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$5.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td align="right">900</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$9.7</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$5.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td align="right">900</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$9.5</td>
<td>$8.6</td>
<td>$9.4</td>
<td>$5.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td align="right">800</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$9.6</td>
<td>$8.6</td>
<td>$9.4</td>
<td>$5.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td align="right">700</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$9.6</td>
<td>$8.6</td>
<td>$9.4</td>
<td>$5.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td align="right">500</td>
</tr>
</tbody>
</table>
</p>
<h3>About Capricor Therapeutics</h3>
<p>Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.</p>
<p>Having examined the options trading patterns of Capricor Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Capricor Therapeutics</h3>
<ul>
<li>With a volume of 1,116,123, the price of CAPR is up 2.91% at $13.77. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Capricor Therapeutics</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $30.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $30. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Capricor Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of Capricor Therapeutics's Latest Options Trends

<p>During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $58.2, a high estimate of $77.00, and a low estimate of $30.00. Holding firm without variation, the current average remains at the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747249230_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Capricor Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Capricor Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Capricor Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Capricor Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Capricor Therapeutics: A Closer Look</h2>
<p>Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.</p>
<h3>Capricor Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Capricor Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-7.92%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-63.94%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Capricor Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-6.66%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.4%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics

<p>Cantor Fitzgerald  analyst Kristen Kluska   reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $30 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $30 Price Target

<p>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.32) by 65.63 percent. This is a 70.97 percent decrease over losses of $(0.31) per share from the same period last year.</p>


Earnings

Earnings Misses

Capricor Therapeutics Q1 EPS $(0.53) Misses $(0.32) Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CINT

CLPT

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

<p>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Capricor Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.32.</p>
<p>Capricor Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.15, leading to a 17.51% increase in the share price the following trading session.</p>
<p>Here's a look at Capricor Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.31</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.38</td>
<td>-0.35</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>18.0%</td>
<td>9.0%</td>
<td>9.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076571_0.png" alt="eps graph" /></p>
<h3>Market Performance of Capricor Therapeutics's Stock</h3>
<p>Shares of Capricor Therapeutics were trading at $6.34 as of May 09. Over the last 52-week period, shares are up 37.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Capricor Therapeutics</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Capricor Therapeutics.</p>
<p>The consensus rating for Capricor Therapeutics is Buy, derived from 4 analyst ratings. An average one-year price target of $65.25 implies a potential 929.18% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Rigel Pharmaceuticals, with an average 1-year price target of $39.75, suggesting a potential 526.97% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 21.14% downside.</li>
<li>Analysts currently favor an Buy trajectory for Abeona Therapeutics, with an average 1-year price target of $16.5, suggesting a potential 160.25% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-29.86%</td>
<td>$71.30M</td>
<td>-6.32%</td>
</tr>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>Buy</td>
<td>80.58%</td>
<td>$48.92M</td>
<td>104.74%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Abeona Therapeutics</td>
<td>Buy</td>
<td>0.00%</td>
<td>$0</td>
<td>-20.70%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Capricor Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it ranks in the middle for Return on Equity, suggesting a moderate level of profitability relative to others.</p>
<h3>Unveiling the Story Behind Capricor Therapeutics</h3>
<p>Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.</p>
<h3>Breaking Down Capricor Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Capricor Therapeutics faced challenges, resulting in a decline of approximately <strong>-7.92%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Capricor Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-63.94%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Capricor Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-6.66%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.4%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Capricor Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/CAPR/earnings"><strong>To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Capricor Therapeutics's Earnings Forecast

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Comments

Capricor Therapeutics

ニュース

最新ニュース Capricor Therapeutics (NASDAQ:CAPR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル